BridgeBio have significantly improved its development of a new treatment for cardiac amyloidosis, employing Attruby. Initial clinical information indicates significant improvements for individuals suffering with the https://biotech776592.tokka-blog.com/42566978/firm-improves-cardiac-amyloidosis-management-using-the-therapy